Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genenta Science S.p.A.GNTA · Entity 7215 | Chief Financial Officer | March 30, 2026 | April 01, 2026 |
| ONCOSEC MEDICAL IncONCS · Entity 117092 | Chief Financial Officer | June 15, 2018 | July 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genenta Science S.p.A.
Report date March 30, 2026 · Filed April 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2035-12-31 | Direct | 80,000 |
Reported balance
After 2026-03-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-30 · Grant · Acquired 80,000 · Balance 80,000 F1: The stock options vest in equal monthly installments over three years beginning March 30, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options vest in equal monthly installments over three years beginning March 30, 2026.
ONCOSEC MEDICAL Inc
Report date June 15, 2018 · Filed July 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 255,000 |
Reported balance
After 2018-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-06-15 · Exercise / conversion · Acquired 100,000 · Balance 255,000 F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. |
| Common StockSEC Table I · non-derivative | Direct | 355,000 |
Reported balance
After 2018-06-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-06-15 · Exercise / conversion · Acquired 100,000 · Balance 355,000 F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. |
| Common StockSEC Table I · non-derivative | Direct | 342,387 |
Reported balance
After 2018-06-18 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2018-06-18 · Sale · Disposed 12,613 · Balance 342,387 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 338,216 |
Reported balance
After 2018-06-19 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2018-06-19 · Sale · Disposed 4,171 · Balance 338,216 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 313,310 |
Reported balance
After 2018-06-20 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2018-06-20 · Sale · Disposed 24,906 · Balance 313,310 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 308,366 |
Reported balance
After 2018-06-21 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2018-06-21 · Sale · Disposed 4,944 · Balance 308,366 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 301,656 |
Reported balance
After 2018-06-22 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2018-06-22 · Sale · Disposed 6,710 · Balance 301,656 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 301,198 |
Reported balance
After 2018-06-25 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2018-06-25 · Sale · Disposed 458 · Balance 301,198 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 290,525 |
Reported balance
After 2018-06-26 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2018-06-26 · Sale · Disposed 10,673 · Balance 290,525 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 282,693 |
Reported balance
After 2018-06-27 transaction · row 10
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 10 · 2018-06-27 · Sale · Disposed 7,832 · Balance 282,693 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 279,161 |
Reported balance
After 2018-06-28 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2018-06-28 · Sale · Disposed 3,532 · Balance 279,161 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 276,741 |
Reported balance
After 2018-06-29 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2018-06-29 · Sale · Disposed 2,420 · Balance 276,741 F2: Sale to cover taxes on restricted stock unit vesting. |
| Common StockSEC Table I · non-derivative | Direct | 270,016 |
Reported balance
After 2018-07-05 transaction · row 13
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 13 · 2018-07-05 · Sale · Disposed 6,725 · Balance 270,016 F2: Sale to cover taxes on restricted stock unit vesting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2019-03-04 | Direct | 0 |
Reported balance
After 2018-06-15 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-06-15 · Exercise / conversion · Disposed 100,000 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2020-03-29 | Direct | 0 |
Reported balance
After 2018-06-15 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-06-15 · Exercise / conversion · Disposed 100,000 · Balance 0 F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
F2: Sale to cover taxes on restricted stock unit vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 30, 2026 Filed Apr 1, 2026 20:05 UTC | Genenta Science S.p.A. GNTA · Entity 7215 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001493152-26-014629 · ownership.xml · derivative · entry 1 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: American Depositary Shares · 80,000 shares Expires 2035-12-31 F1 · derivative.exercise_date: The stock options vest in equal monthly installments over three years beginning March 30, 2026. Read SEC document |
| July 05, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 6,725 | $1.31 | $8,823.20 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 13 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,016 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 29, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 2,420 | $1.38 | $3,339.60 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 12 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,741 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 28, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 3,532 | $1.40 | $4,948.33 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 11 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,161 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 27, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 7,832 | $1.37 | $10,761.17 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 10 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,693 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 26, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 10,673 | $1.40 | $14,920.85 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 9 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,525 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 25, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 458 | $1.41 | $643.49 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 8 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,198 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 22, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 6,710 | $1.42 | $9,514.78 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 7 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,656 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 21, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 4,944 | $1.40 | $6,926.54 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 6 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,366 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 20, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 24,906 | $1.42 | $35,416.33 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 5 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,310 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 19, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 4,171 | $1.36 | $5,689.24 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 4 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,216 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 18, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | SaleCommon Stock | 12,613 | $1.39 | $17,481.62 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 3 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,387 F2 · security: Sale to cover taxes on restricted stock unit vesting. Read SEC document |
| June 15, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Exercise / conversionRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · derivative · entry 15 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2020-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document |
| June 15, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Exercise / conversionRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · derivative · entry 14 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2019-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document |
| June 15, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Exercise / conversionCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 2 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document |
| June 15, 2018 Filed Jul 6, 2018 16:40 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Exercise / conversionCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-009768 · ownership.xml · nonDerivative · entry 1 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:21 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $1.47 Strike: $1.47 | $147,000.00 |
DisclosureSEC source: 0001493152-18-006354 · form4.xml · derivative · entry 1 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,500 Underlying: Common Stock · 100,000 shares Expires 2028-05-03 F1 · derivative.exercise_price: OncoSec's (ONCS) stock closing price was $1.47 on May 3, 2018. F2 · derivative.exercise_date: 25% vested on the Grant Date of May 3, 2018, and the remaining 75% are vesting in 36 equal monthly increments, which began on the first monthly anniversary of the Grant Date, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 16:23 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001493152-18-000655 · form4.xml · derivative · entry 1 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,500 Underlying: Common Stock · 100,000 shares Expires 2027-11-04 F1 · derivative.exercise_price: OncoSec's (ONCS) stock closing price was $1.32 on November 4, 2017. F2 · date: The Stock Options to purchase 100,000 shares of common stock of the issuer were approved by OncoSec's Board of Directors on November 4, 2017 ("Grant Date") and the contingency restriction was removed after OncoSec's Annual Stockholders Meeting held on January 12, 2018. F2 · shares: The Stock Options to purchase 100,000 shares of common stock of the issuer were approved by OncoSec's Board of Directors on November 4, 2017 ("Grant Date") and the contingency restriction was removed after OncoSec's Annual Stockholders Meeting held on January 12, 2018. F3 · derivative.exercise_date: 25% vested on January 12, 2018, and the remaining 75% are vesting in 36 equal monthly increments, which began on the first monthly anniversary of the Grant Date, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 21:45 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantOption to Purchase Common Stock · Derivative | 75,000 | $1.34 Strike: $1.34 | $100,500.00 |
DisclosureSEC source: 0001493152-17-003332 · form4.xml · derivative · entry 2 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,500 Underlying: Common Stock · 75,000 shares Expires 2027-03-29 F3 · derivative.exercise_date: 25% vested on the Grant Date, and the remaining 75% to vest in 36 equal monthly increments, beginning on the first monthly anniversary of the Grant Date, pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| March 29, 2017 Filed Mar 31, 2017 21:45 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantRestricted Stock Units · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-17-003332 · form4.xml · derivative · entry 1 SLANSKY RICHARD B · CIK 0001224981 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2020-03-29 F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit. F2 · derivative.exercise_date: 100% of the restricted stock units are scheduled to vest on March 29, 2020, assuming continued employment and/or service through the applicable vesting date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 17:28 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantEmployee Stock Option (right to buy) · Derivative | 112,500 | Not disclosed Strike: $1.29 | Not disclosed |
DisclosureSEC source: 0001493152-16-015979 · form4.xml · derivative · entry 3 SLANSKY RICHARD B · CIK 0001224981 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2026-12-14 F4 · security: These stock options were granted as Incentive Stock Options only to the extent that the $100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 150000 shares (previously granted on July 6, 2015) and 75000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 112500 shares of common stock with an exercise price of $1.29 per share. F6 · derivative.exercise_date: The stock options granted on December 14, 2016 will vest on the following schedule: 25% on grant date; 1/36th of the remaining 75% vesting on each of the 36 subsequent monthly anniversaries of the grant date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 17:28 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $5.76 | Not disclosed |
DisclosureSEC source: 0001493152-16-015979 · form4.xml · derivative · entry 2 SLANSKY RICHARD B · CIK 0001224981 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2025-08-21 F4 · security: These stock options were granted as Incentive Stock Options only to the extent that the $100,000 dollar limitation of 26 U.S.C. ss.422(d) is not exceeded; anything beyond that is deemed a Non-qualified Stock Option. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 150000 shares (previously granted on July 6, 2015) and 75000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 112500 shares of common stock with an exercise price of $1.29 per share. F5 · derivative.exercise_date: These stock options are scheduled to fully vest on August 21, 2018, the third anniversary of the grant date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 17:28 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | Disposition to issuerNon-qualified Stock Option (right to buy) · Derivative | 150,000 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001493152-16-015979 · form4.xml · derivative · entry 1 SLANSKY RICHARD B · CIK 0001224981 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 150,000 shares Expires 2025-07-06 F1 · security: These stock options were granted as Non-qualified stock options. F3 · price: On December 14, 2016, OncoSec Medical Incorporated cancelled, pursuant to its Stock Option Exchange Program, options previously granted to and held by the reporting person to purchase 150000 shares (previously granted on July 6, 2015) and 75000 shares (previously granted on August 21, 2015) of common stock. In exchange, and subject to the terms of the Stock Option Exchange Program, the reporting person received a replacement option for 112500 shares of common stock with an exercise price of $1.29 per share. F2 · derivative.exercise_date: These stock options are scheduled to fully vest on July 6, 2018, the third anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.